SLC5A2 and chronic kidney disease: Furthermore, cardioprotective and renoprotective effects have been reported in a series of large-scale clinical trials in recent years (EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS, DAPA-CKD, CREDENECE, EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER) (1–9), and the patients treated with SGLT2 inhibitors is rapidly increasing.